Clin2
NCT07598643Likely a fitRecruiting

Immune System Treatment to Help Down Syndrome Development

Down Syndrome

Treatments studied

Part of Brain & nervous system, Genetic & congenital clinical trials.

This study tests a medication called tofacitinib that modulates the immune system in children and young adults with Down syndrome aged 6–22 years. The goal is to see if it can improve brain development and overall health outcomes over 6 months.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
92 people
Ages
6 years to 22 years
Study type
Interventional

Who can take part

  • Age 6 to 22 years old with Down syndrome (any type)
  • Parent or guardian available to sign consent and complete study materials
  • Body weight of at least 10 kg (about 22 lbs)
  • No recent treatment with JAK inhibitors or other experimental agents in the past 3 weeks
  • No active serious infections, blood clots, or cancer history
  • Able to have repeated blood tests and complete developmental assessments

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07416201Recruiting
Study of Immune System Aging in Down Syndrome

This study is looking at how the immune system changes over time in people with Down syndrome, and how it may be affected by removal of the thymus gland. The goal is to understand why people with Down syndrome may age faster or have different immune health.

Bethesda, Maryland
NCT07531940Not yet recruiting· Phase 1
Testing Memantine Doses in Down Syndrome

This study tests whether a medicine called memantine (already used for memory problems) can help people with Down syndrome think and remember better. Researchers will try different doses to find what works best and is safest.

Cleveland, Ohio
NCT06465823Recruiting· Phase 2
Bumetanide for thinking skills in Down syndrome

This trial tests whether a medication called bumetanide can improve thinking and learning skills in teenagers with Down syndrome. It is a 10-week study that compares bumetanide to a placebo (a pill with no medicine).

Rome
NCT06689982Not yet recruiting· Early Phase 1
Tofacitinib for people with ALS and a specific immune profile

This study tests a drug called tofacitinib, which calms the immune system, in people with ALS. It aims to see if it can slow the disease by blocking an overactive immune response linked to certain genetic patterns.

Beijing
NCT07278492Not yet recruiting· Phase 1
NAD boost to prevent Alzheimer's in Down syndrome

This study tests whether a supplement that boosts a natural substance called NAD (which helps cells work properly) can slow or stop memory loss in people with Down syndrome. You and your caregiver would visit a clinic for regular checkups and take the supplement daily.

Boston, Massachusetts
NCT07334912Recruiting· Phase 2
Study of AEF0217 for people with Down syndrome

This study tests if an investigational drug called AEF0217 can help improve thinking and daily living skills in people with Down syndrome. It's for ages 16-32 who have a caregiver to support them throughout the trial.

Bordeaux

Hear when a new Down Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.